Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

25th World Congress on Cancer Science and Therapy

Baltimore, USA

Porunelloor A Mathew

University of North Texas Health Science Center, USA

Title: CS1 (CD319) is an effective immunotherapeutic target for multiple myeloma

Biography

Biography: Porunelloor A Mathew

Abstract

Multiple Myeloma (MM) is a cancer of the plasma cells and is fatal without treatment due to anemia, renal failure, hypercalcemia, and bone destruction. Natural killer (NK) cells, a component of the innate immune system, function against infection and cancer. Identification and characterization of NK cell receptors lead to a better understanding of the molecular basis of Natural Killer cell recognition and activation by cancer cells. NK cell functions are regulated by a delicate balance between signaling through activating receptors and inhibitory receptors. We have identified and characterized CS1 (CD319, SLAMF7, CRACC) as an NK cell receptor activating its function through homophilic interactions. A monoclonal antibody against CS1 induced both Natural cytotoxicity and ADCC (Antibody-dependent cell-mediated cytotoxicity) by NK cells. CS1 is overexpressed on MM cells and anti- CS1 mAb enhance the killing of MM by NK cells. Elotuzamab (Empliciti) is a humanized monoclonal antibody against CS1, and has been aproved as a breakthrough drug against MM. During clinical trails, Empliciti in combination with chemotherapeutic drugs showed more effective than antibody treatment alone. However, the underlying mechanism for this is not known. We hypothesize that chemotherapeutic drugs induce the expression of CS1 on MM cells making them more susceptible to NK mediated killing. To investigate this property, MM cells were incubated with various combinations of chemotherapy and immunotherapy drugs in order to observe any change in surface expression of CS1. Our results indicate that treatment with anti-CS1 in combination with lenalidomide or doxorubicin and dexamethasone increased the cell surface expression of CS1. Thus enhancing the expression of molecular targets for NK cells is an effective strategy for immunotherapy of cancer.